Esperite NV (ESP) - Financial and Strategic SWOT Analysis Review

December 2018 | 55 pages | ID: EC004227796EN
GlobalData

Abstracts

Esperite NV (ESP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Key manufacturing facilities – A list of key manufacturing facilities of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Esperite NV (Esperite) is a regenerative and precision medicine company. It collects, processes and stores human adult stem cells obtained from umbilical cord blood and cord tissue. Esperite offers a diagnostic system built on the Next Generation Sequencing technology (NGS) that enables laboratories for performing with bioinformatics-based genetic analysis. The company operates a research and development division, the Cell Factory, which is involved in developing advanced cell therapy medicinal products and new therapies in the field of regenerative medicine. The company works in partnership with pharmaceutical and biotechnology companies to advance the development of its products and services. Esperite is headquartred in Amsterdam, the Netherlands.

Esperite NV Key Recent Developments

Nov 23,2018: ESPERITE: financial results for 2017 are published
Nov 06,2018: Esperite Group with The Cell Factory expands its Extracellular Vesicles product portfolio of anti-inflammatory drugs with a fourth indication: Bronchopulmonary Dysplasia.
Sep 13,2018: Esperite with Cryosave ready to store more than a million samples in its new designed cryostorage facility in geneva
Jun 19,2018: Esperite N.V. secures external financing of up to EUR 5 million to support its commercial activity and development of innovative technologies
Jun 11,2018: European Select Growth Opportunities Fund subscribes to the 19th tranche of its investment today and has agreed to provide up to EUR 7.25 million in additional funding

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Esperite NV - Key Facts
Esperite NV - Key Employees
Esperite NV - Key Employee Biographies
Esperite NV - Major Products and Services
Esperite NV - History
Esperite NV - Company Statement
Esperite NV - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Esperite NV - Business Description
Business Segment: Genoma
Overview
Performance
Business Segment: Holding
Overview
Performance
Business Segment: Other
Overview
Performance
Business Segment: Stem Cell
Overview
Performance
Business Segment: The Cell Factory
Overview
Performance
Esperite NV - SWOT Analysis
SWOT Analysis - Overview
Esperite NV - Strengths
Esperite NV - Weaknesses
Esperite NV - Opportunities
Esperite NV - Threats
Esperite NV - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Esperite NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Esperite NV, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Esperite NV, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Nov 23, 2018: ESPERITE : financial results for 2017 are published
Sep 13, 2018: Esperite with Cryosave ready to store more than a million samples in its new designed cryostorage facility in geneva
Jun 19, 2018: Esperite N.V. secures external financing of up to EUR 5 million to support its commercial activity and development of innovative technologies
Jun 11, 2018: European Select Growth Opportunities Fund subscribes to the 19th tranche of its investment today and has agreed to provide up to EUR 7.25 million in additional funding
Mar 29, 2018: Esperite, The Cell Factory presents pre-clinical results on the new products of the 2nd generation EV's drugs for treatment of inflammatory diseases
Jan 10, 2018: ESPERITE transfers its laboratory activity to Geneva and consequently sells its Belgium loss making subsidiary and avoids EUR 4 millions of future cash out for charges and financial costs
Oct 09, 2017: Esperite with CryoSave enters the Ukrainian market and fosters its leadership position in Europe
Oct 02, 2017: ESPERITE publishes its half-year report
May 31, 2017: ESPERITE Q1 consolidated revenue higher compared to budget
May 23, 2017: Esperite Financial Results For 2016 Published

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Esperite NV, Key Facts
Esperite NV, Key Employees
Esperite NV, Key Employee Biographies
Esperite NV, Major Products and Services
Esperite NV, History
Esperite NV, Subsidiaries
Esperite NV, Key Competitors
Esperite NV, Ratios based on current share price
Esperite NV, Annual Ratios
Esperite NV, Annual Ratios (Cont.1)
Esperite NV, Interim Ratios
Esperite NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Esperite NV, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Esperite NV, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Esperite NV, Performance Chart (2013 - 2017)
Esperite NV, Ratio Charts
Esperite NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Esperite NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

COMPANIES MENTIONED

Virgin Health Bank
NHS Cord Blood Bank
New England Cord Blood Bank, Inc
Cryopraxis Criobiologia Ltda
Cells4Life Group LLP